At BeyondSpring, we hold true to our core values, which influence every decision we make for the #cancer patients we serve. Our second value, respect, is woven into all that we do as we interact with each other & the patients who believe in us. Learn more: bit.ly/3lHgwp1

For this month’s #EmployeeSpotlight, we’re highlighting Senior Scientist, Clinical Strategy, Jasmine Wells. She has over 7 years of clinical experience as a physician assistant including in #hematology and #oncology. Learn more about our team here: bit.ly/3jR6jFF

At BeyondSpring, our employees are the heart of our company, and our third core value, organizational excellence, is of utmost importance as we continue working towards our mission of improving the lives of #cancer patients in need. Learn more: bit.ly/35giaZT

Today we would like to highlight our sponsored research agreement with MD Anderson Cancer Center over the last four years to evaluate the benefits of adding our lead asset to #RadiationTherapy plus immune checkpoint antibodies in multiple cancers. Learn more here: bit.ly/3N8GXQT

#DYK that today is #WorldLungCancerDay? #LungCancer is the most common #cancer worldwide and claims more lives yearly than breast, colon & prostate cancers combined. Learn more about our non-small cell lung cancer program here: bit.ly/3PVOgMp

For this month’s #EmployeeSpotlight, we’re highlighting VP of #ClinicalOperations, Michael Snyder. He has over 20 years of #ClinicalResearch experience at global #pharmaceutical companies delivering quality #ClinicalTrials. Learn more about our team here: bit.ly/3jR6jFF

#Cancer is relentless and so are we when it comes to our team's dedication to developing innovative therapies. Here at BeyondSpring, we would not be where we are today without adhering to our fourth and final value of #WorkingTogether. Learn more: bit.ly/35giaZT

Today we announced data from our Memorial Sloan Kettering Cancer Center #ClinicalTrial that evaluates how our lead asset can potentially decrease neutropenia burden in peri-transplant #MultipleMyeloma patients at the 19th International Myeloma Society Meeting. Learn more here: bit.ly/3KwUgtp

We presented a poster at The European Society for Medical Oncology (ESMO - Eur. Oncology) Congress analyzing the potential of our lead asset combined with the standard of care to prevent chemotherapy-induced #neutropenia by protecting stem cells. Learn more: bit.ly/3TZlfCe #ESMO22

For this month’s #EmployeeSpotlight, we’re highlighting Regulatory Affairs Manager, Jennifer Dufour, who brings #RegulatoryAffairs experience from the Dana-Farber #Cancer Institute and Georgetown's Georgetown Lombardi Cancer Center. Learn more about our team: bit.ly/3jR6jFF

#DYK that Saturday is #WorldCancerResearchDay? The day is dedicated to promoting #CancerResearch and we're proud to be driving progress in this area with our #cancer therapies. Learn more about our robust #oncology pipeline and research here: bit.ly/3PVOgMp

Sunday is #WorldLungDay! Here at BeyondSpring, we are dedicated to promoting better #LungHealthForAll by developing a potential treatment for #LungCancer. Learn more: bit.ly/3PBPn3n

#ICYMI, Dr. Trevor Feinstein spoke with CancerNetwork® about the data presented at #ASCO22 on our non-small cell lung cancer program. Learn more here: bit.ly/3RoeV5v

Come meet us at Social in the City Annual Meeting in sunny San Diego next week! beyondspringpharma.com/beyondspring-a…

BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models $BYSI healthstockshub.com/news/nasdaq/by…

Pharma/Biotech Highlights: $BYSI: Potential glioblastoma treatment Plinabulin shows promise. $ARDX: Ardelyx updates financial results and guidance. $ALZH: Alzheon CEO shares hopeful Alzheimer's findings. $LLY: Verve and Lilly collaborate on gene editing for PCSK9 and ANGPTL3.

“Targeted Protein Degradation Think Tank” Symposium at Seed Therapeutics #TPD youtu.be/glao39LAzVE

SEED Achieved 3rd Milestone with Lilly R&D Collaboration. Seed Therapeutics #TPD